Ozempic in Hong Kong: What It Is, Where to Get It, and What to Expect (2026)
Why GLP-1 Drugs Have Changed Weight Management in Hong Kong
Over the past three years, GLP-1 receptor agonists (this is the class of drugs that includes Ozempic, Wegovy, and Mounjaro) have transformed how doctors and patients approach weight management. In Hong Kong, demand has grown steadily since Ozempic was first approved for diabetes treatment, and more recently as its weight management applications became widely understood.
Searches for "ozempic hong kong" have risen sharply, and for good reason: these medications produce meaningful, medically supervised weight loss in a way that diet and exercise alone often cannot. But they are prescription medications that require proper clinical oversight, and navigating what's available, who qualifies, and what a treatment programme actually looks like can be confusing.
This guide covers everything relevant to patients in Hong Kong. We'll answer what Ozempic is, how it works, who it's appropriate for, what it costs, and how REVIV's GLP-1 weight management programme is structured.
What Is Ozempic?
Ozempic is the brand name for semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist originally developed by Novo Nordisk to treat type 2 diabetes. It is administered as a once-weekly subcutaneous injection.
GLP-1 is a hormone naturally produced in the gut after eating. It signals the pancreas to release insulin, slows gastric emptying (meaning food moves more slowly from the stomach to the small intestine), and it acts on the brain's appetite centres to reduce hunger.
Semaglutide mimics this hormone but with a much longer half-life, keeping these effects active throughout the week. The result is reduced appetite, lower caloric intake, improved blood sugar regulation, and over time, significant weight loss.
Wegovy is a higher-dose formulation of the same molecule (semaglutide 2.4mg vs Ozempic's 0.5–2mg), specifically approved for weight management rather than diabetes. In clinical trials, people using semaglutide at the Wegovy dose lost an average of 15% of their body weight over 68 weeks.
Is Ozempic Available in Hong Kong?
Yes. Ozempic (semaglutide) is registered with Hong Kong's Department of Health and is available via prescription. It is approved primarily for adults with type 2 diabetes, though doctors may also prescribe it off-label for weight management in eligible patients.
Ozempic is a prescription-only medication in Hong Kong. It cannot be purchased over the counter or imported without a valid prescription. Under Hong Kong pharmacy regulations, prescription injections can only be dispensed by a registered pharmacist under a valid prescription from a licensed practitioner.
Mounjaro (tirzepatide), a newer dual GIP/GLP-1 receptor agonist from Eli Lilly, received regulatory approval in Hong Kong in late 2024 for both chronic weight management and type 2 diabetes. It's the first drug in Hong Kong approved via the dual-receptor mechanism.
Who Is Eligible for GLP-1 Treatment?
Eligibility is determined during a medical consultation and depends on several factors. Generally, GLP-1 medications are appropriate for adults who meet one or more of the following:
BMI of 30 or above (classified as obese)
BMI of 27 or above with at least one weight-related health condition such as hypertension, dyslipidaemia, type 2 diabetes, or obstructive sleep apnoea
A history of difficulty achieving or sustaining weight loss through diet and lifestyle changes alone
GLP-1 medications are not suitable for people with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or pancreatitis. Pregnancy and breastfeeding are also contraindications. A full medical history and blood panel are required before starting treatment.
How REVIV's GLP-1 Weight Management Programme Works
REVIV's approach to weight management is built around medical supervision, metabolic support, and sustainable results. The programme is a clinically structured programme with ongoing monitoring.
The typical patient journey looks like this:
Initial consultation with a doctor — A registered medical practitioner reviews your health history, BMI, relevant bloods, and weight loss goals. This determines whether a GLP-1 medication is appropriate for you and, if so, which one and at what starting dose.
Baseline bloodwork — Where required, relevant markers including fasting glucose, HbA1c, liver function, kidney function are reviewed to establish a baseline and screen for contraindications.
Dose titration — GLP-1 medications are started at a low dose and increased gradually over several weeks to minimise side effects. Your clinical team monitors progress at each stage.
Ongoing support — Regular check-ins with the clinical team to adjust dose, manage any side effects, and track progress. Many patients also incorporate IV nutritional support (such as NAD+ or Vitaglow) alongside the programme to maintain energy levels during caloric restriction.
Lifestyle integration — The medication is most effective as part of a broader approach that includes dietary guidance and physical activity. REVIV's team can advise on this throughout.
The programme is available to new patients by appointment. First-time patients must complete a doctor's consultation before any treatment is initiated.
Ozempic vs Wegovy vs Mounjaro: Key Differences
The table below summarises the key differences between the three main GLP-1/dual-agonist medications available in Hong Kong:
Ozempic — Active ingredient: Semaglutide. Mechanism: GLP-1 agonist. Primary approval: Type 2 diabetes. Average weight loss: ~10–12%.
Wegovy — Active ingredient: Semaglutide (higher dose). Mechanism: GLP-1 agonist. Primary approval: Weight management. Average weight loss: ~15%.
Mounjaro — Active ingredient: Tirzepatide. Mechanism: GLP-1 + GIP dual agonist. Primary approval: Diabetes + weight. Average weight loss: ~20–22%.
The right choice depends on your medical history, current health status, and weight loss goals. Your nurse or doctor will advise on which option might be appropriate during the initial consultation.
What to Expect: Side Effects and Timeline
Common side effects
The most frequently reported side effects are gastrointestinal and typically occur during the dose titration phase:
Nausea (most common, usually subsides after a few weeks)
Reduced appetite
Constipation or loose stools
Mild fatigue
These effects are generally mild to moderate and diminish as the body adjusts to the medication. Eating smaller, lower-fat meals and staying well hydrated helps manage them significantly. IV hydration and nutritional support can also be useful during the initial adjustment period.
Timeline
Weeks 1–4: Starting dose. Appetite reduction typically noticeable within the first week. Some nausea possible.
Months 1–3: Gradual dose increase. Most patients see measurable weight loss by week 8–12.
Months 3–6: Continued weight loss. Most clinical trial participants reached their desired weight between months 4–6 before plateauing.
Beyond 6 months: Maintenance phase. Long-term use is often required to sustain results, as weight typically returns if the medication is stopped without lifestyle changes in place.
How Much Does GLP-1 Treatment Cost in Hong Kong?
Pricing varies between providers and depends on the medication, dose, and level of clinical monitoring included.
As us about pricing for your treatment. We can provide costs of a full treatment cycle upfront.
Frequently Asked Questions
Can I get Ozempic in Hong Kong without a prescription?
No. Ozempic is a prescription-only medication in Hong Kong. It cannot be legally dispensed without a valid prescription from a registered medical practitioner. Be cautious of online sellers or sources offering semaglutide without a prescription. These are unregulated and potentially dangerous.
Do I need to have diabetes to get Ozempic in Hong Kong?
No. While Ozempic's primary approval is for type 2 diabetes, doctors in Hong Kong can prescribe it off-label for weight management in eligible patients. Mounjaro has a dual approval covering both conditions.
How long do I need to take it?
GLP-1 medications are most effective when used as part of a longer-term programme. Many patients use them for 6–12 months or longer. Stopping the medication without sustainable lifestyle changes in place typically results in weight returning. Your doctor will help you plan a realistic duration.
What happens if I miss an injection?
If you miss a dose and it has been less than 5 days since the scheduled day, take it as soon as possible. If it has been more than 5 days, skip the missed dose and take the next one on the regular scheduled day. Never take two doses at once.
Can I combine GLP-1 treatment with IV therapy?
Yes, and many REVIV patients do. IV nutritional support — particularly NAD+ and Vitaglow — complements GLP-1 treatment well. Caloric restriction during weight loss can reduce key micronutrients; IV therapy delivers these directly into the bloodstream, bypassing the digestive system that may be affected by the medication.
Is Mounjaro better than Ozempic?
Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, whereas Ozempic activates only GLP-1. Clinical trial data shows higher average weight loss with tirzepatide (~20–22% vs ~15% for semaglutide at comparable doses). However, individual responses vary, and the right choice depends on your health profile, medical history, and other factors — which your doctor will assess.
How do I get started?
Book a consultation with REVIV's clinical team. First-time patients will be required to assess eligibility before any treatment begins. Walk-ins are welcome, but booking in advance is recommended to ensure your preferred time is available.
Book a GLP-1 Consultation at REVIV Hong Kong
REVIV's weight management programme is doctor-led and built around your individual health profile. If you're considering GLP-1 treatment in Hong Kong, the first step is a clinical consultation to determine whether it's appropriate for you.
Location: 1st Floor, The Plaza, 21 D'Aguilar Street, Central, Hong Kong
Opening hours: Monday to Sunday, 10:00 AM – 7:00 PM
WhatsApp: +852 9867 9183
The material on this page is provided for informational purposes only and is not medical advice. Always consult your doctor before beginning any therapy programme. All therapies are subject to medical screening and doctor consultation to approve responsible treatment.
Sources
Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021.
Drucker DJ. GLP-1 Physiology Informs the Pharmacotherapy of Obesity. New England Journal of Medicine, 2022.
Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016.
Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
Hong Kong Department of Health — Pharmacy and Poisons Ordinance: Prescription Drugs.
Novo Nordisk. Ozempic (semaglutide) prescribing information and patient resources.
